News | November 17, 2025
Remedium Lifecare posts consolidated Q2 FY26 net profit higher at Rs. 8.62 Cr
Consolidated revenue from operations stood at Rs. 111.05 crore
Consolidated revenue from operations stood at Rs. 111.05 crore
With US$ 30.46 billion in exports and robust manufacturing capabilities, the industry is poised to expand into high-value drugs while strengthening ESG and compliance standards
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
Total income for the period stood at Rs. 7101.28 crore
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
This remarkable increase from 17 in 2021 ranks among the fastest for pharmaceutical companies, establishing Lupin as a leader in sustainable growth
Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
LANXESS will highlight its commitment to combatting antimicrobial resistance by presenting science-based disinfection solutions
Hyaluronic acid is among the world's most valuable biopolymers, with applications spanning from dermal fillers and wound healing to drug delivery and tissue engineering
Subscribe To Our Newsletter & Stay Updated
